Folliculitis decalvans: a multicentre review of 82 patients

Vañó‐Galván, Sergio; Molina-Ruiz, Ana María; Fernández‐Crehuet, Pablo; Rodrigues-Barata, Ana Rita; Arias‐Santiago, Salvador; Serrano-Falcón, C.; Martorell, A.; Barco, D.; Pérez, Bibiana; Serrano, Salvio; Requena, Luis; Grimalt, Ramón; Paoli, John; Jaén, Pedro; Camacho, Francisco

doi:10.1111/jdv.12993

Cited by 86 publications

(143 citation statements)

References 23 publications

(88 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients complaining of trichodynia also have confirmed inflammatory conditions, such as alopecia areata and folliculitis decalvans, supporting the view that trichodynia is a symptom of the underlying inflammation . Notably, if inflammation is its causative agent, trichodynia would be a warning symptom of the impending shedding wave, which, however, would occur 3 months after the beginning of trichodynia, according to the interval between the hair entry into telogen phase and the disconnection of the hair shaft .…”

Section: Pathogenesismentioning

confidence: 86%

Trichodynia: a review of the literature

Rebora

2015

Int J Dermatology

View full text Add to dashboard Cite

Trichodynia designates a painful sensation on the scalp sometimes reported by patients with hair loss. Its best description dates back to 1960, when Sulzberger et al. (Arch Dermatol 1960; 81: 556-560) reported it in a proportion of women complaining of an unexplained diffuse alopecia. Sulzberger et al.'s remark that trichodynia may also be circumscribed ("spotty") is an important detail missed by most ensuing observers. Women are mostly affected or, at least, more likely to report it. The quality and intensity vary greatly, the "burning" variety being most severe. Whether trichodynia is prevalent in telogen effluvium or it may also be present in androgenetic alopecia remains a crucial question. Hairs shed only from painful sites, and this observation suggests that the severity of trichodynia is directly related to hair shedding and intensity. Trichodynia seems to be related to the release of substance P and is present in alopecia areata. Both observations suggest that peripilar inflammation may be a causative agent.

show abstract

Section: Pathogenesismentioning

confidence: 86%

Trichodynia: a review of the literature

Rebora

2015

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“…Interestingly, FD patients associate their alopecia with a poor medical care in their past, but they still believe that medical treatment can control the disease. Considering the multiple choices of treatment available for FD [2], we must provide the best option to each patient.…”

Section: Discussionmentioning

confidence: 99%

“…FD severity was classified into 3 grades according to the scale of Vañó-Galván et al [2]. We used the Spanish version of validated questionnaires to measure dermatology-specific QoL (Dermatology Life Quality Index: DLQI), health-related QoL (Short Form 12 Health Survey version II: SF-12), and perception of disease (Revised Illness Perception Questionnaire: IPQ-R) [3,4,5].…”

Section: Methodsmentioning

confidence: 99%

Impact of Folliculitis Decalvans on Quality of Life and Subjective Perception of Disease

Pindado‐Ortega¹,

Saceda‐Corralo²,

Miguel‐Gomez³

et al. 2017

Skin Appendage Disord

View full text Add to dashboard Cite

Folliculitis decalvans (FD) is a primary neutrophilic scarring alopecia characterized by perifollicular papules, crusts, and pustules frequently located on the vertex. FD may affect young men and women. Since it may lead to hair loss, it can have a negative impact on patients' quality of life. Nevertheless, studies have focused on clinical, prognostic, and therapeutic aspects without considering the psychological impact of FD. In our study, we found that FD patients experienced a considerable impact on their quality of life. Interestingly, almost half of the patients considered that their alopecia was related to a poor medical care in their past. To our knowledge, this is the first description of the impact of FD on patients' quality of life, and it highlights the importance of psychological support for these patients.

show abstract

“…The condition typically starts at the crown and vertex area [3]. More than two thirds (68 %) of FD patients experience pruritus, while 30 % of patients suffer from pain, called trichodynia [7].…”

mentioning

confidence: 99%

“…Tetracyclines or in severe non-responding cases clindamycin and rifampicin (also effective against intracellular Staphylococcus aureus), often combined with local administration of glucocorticoids, are able to halt the disease in many patients, but not all, by their effects against Staphylococcus aureus and probably also by their anti-inflammatory effects [8,9]. Other therapeutic options include oral corticosteroids, topical antiseptic substances, tacrolimus, isotretinoin, dapsone, and, recently, tumor necrosis factor (TNF) blocking agents (adalimumab and infliximab) [3,6,7]. However, there are still patients in whom these therapeutic options are either not all applicable or not sufficiently efficacious, so that the disease remains active and causes considerable discomfort with pruritus or trichodynia.…”

mentioning

confidence: 99%